A Phase I/II Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 18 Feb 2019 Planned End Date changed from 1 Oct 2020 to 18 Feb 2019.
- 18 Feb 2019 Planned primary completion date changed from 1 Oct 2020 to 18 Feb 2019.
- 18 Feb 2019 Status changed from recruiting to withdrawn prior to enrolment.